Contact us Pulsar®-18 T3 Self-Expanding Stent System A unique combination of 3 technologies indicated for treatment of PAD1 in the lower limb Thin struts, low COF Tri-axial system with braided shaft Low profile delivery system Request Case Report PDF Register for a downloadable PDF of case reports to see what can be achieved with the Pulsar-18 T3 by providing your contact details below. This will also enable your local BIOTRONIK sales organization follow up with you via e-mail. First Name:* Last Name:* Email Address:* Country:* Select... United States Canada Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Croatia Cuba Curaçao Cyprus Czech Republic Côte d’Ivoire Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong S.A.R., China Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao S.A.R., China Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Romania Russia Rwanda Réunion Saint Barthélemy Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu U.S. Virgin Islands Uganda Ukraine United Arab Emirates United Kingdom United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Vatican Venezuela Viet Nam Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Your information will be processed in accordance with our privacy statement. Please note that you can withdraw your consent at any time by sending a message to marketing.vi@biotronik.com or by using the unsubscribe option in our e-mails. Learn more about Pulsar-18 T3 Watch the Pulsar-18 T3 in action to treat multiple SFA stenoses. Case courtesy of Drs. Luis Mariano Palena and Marco Manzi. Clinically Proven Even in Complex Lesions2 Strong results with no significant difference in outcomes between calcified and noncalcified lesions 85.1% 24 - m FTLR 4EVER3 Download Study Flyer Positive results even for long and occluded lesions in a high risk population 86% 12 - m FTLR TASC D4 Download Study Flyer All-comers registry shows sustained results in a real world population 89.3% 24 - m FTLR BIOFLEX PEACE5 (stent only) Download Study Flyer What is COF and why does it matter? Chronic outward force (COF) is the force exerted on the vessel wall by a self-expanding stent to achieve its present diameter.6 Thinner struts, which have lower COF*, result in a lower risk of restenosis, reduced vessel injury and inflammation and faster endothelialization.7,8,9 Thinner struts for lower COF10 Achieve less mean restenosis with low-COF Pulsar-18 T311 *as demonstrated in pre-clinical studies Physician Testimonials 1 2 3 4 5 6 7 How did you find using Pulsar-18 T3 the first time? How does Pulsar-18 T3 meet your treatment objectives? Why is 4-F treatment important for patients? Easy to use, ergonomically designed. The first tri-axial, 4F thin-strut stent system for the treatment of lower limb PAD.1 Download Product Flyer Contact us PAD – Peripheral Artery Disease; Bosiers M. 4EVER 24 month results: long-term results of 4F Pulsar stent in femoropopliteal lesions. Presented at: CIRSE 2013; Barcelona, Spain: Deloose K. 4EVER 24m: Long-term results of 4F Pulsar stents in femoropopliteal lesions. Presented at: LINC; Jan 29, 2014; Leipzig, Germany: Lichtenberg M. Superficial Femoral Artery TASC D registry: 12-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia. J Cardiovasc Surg (Torino). 2013 ; 54(4):433-9; Lichtenberg et al. Effectiveness of the Pulsar-18 self-expanding stent with optional drug-coated balloon angioplasty in the treatment of femoropopliteal lesions - the BIOFLEX PEACE All-Comers Registry.Vasa (2019), 1-9. doi_10.10240301- 1526a000785; Freeman JW, et al. A link between stent radial forces and vascular wall remodeling: the discovery of an optimal stent radial force for minimal vessel restenosis. Connect Tissue Res. 2010 Aug; 54(4): 314-26; Zhao HQ Late stent expansion and neointimal proliferation of oversized nitinol stents in peripheral arteries. Cardiovasc. Interv. Radiol. 2009; 32(4); 720-6; Koskinas C. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. JACC 2012 10;59(15):1337-49; Koppara T. Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents. Circ Cardiovasc Interv.2015 8(6):e002427. BIOTRONIK data on file. 6.0 mm diameters. Supera stent not possible to test due to its design and applied test method; Funovics M. Differences in clinical outcomes of low COF stent vs high COF stent proven in clinical practice. Presented at: CIRSE, Sep 8, 2019; Barcelona, Spain; Pulsar is a trademark or registered trademark of the BIOTRONIK Group of Companies. © 2020 BIOTRONIK. All rights reserved GENERAL TERMS AND CONDITIONS IMPRINT LEGAL DISCLAIMER PRIVACY STATEMENT